AP
NKTR icon

Advisor Partners’s Nektar Therapeutics NKTR Stock Holding History

Advisor Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-479
Closed -$255K – 683
2019
Q2 		$255K Buy
479
+41
+9% +$20.6K 0.03% 516
2019
Q1 		$221K Sell
438
-70
-14% -$41.5K 0.03% 564
2018
Q4 		$251K Buy
508
+166
+49% +$100K 0.04% 465
2018
Q3 		$312K Buy
342
+1
+0.3% +$854 0.04% 437
2018
Q2 		$250K Sell
341
-53
-13% -$61.1K 0.04% 476
2018
Q1 		$628K Buy
394
+28
+8% +$36.1K 0.12% 206
2017
Q4 		$393K Buy
+366
New +$216K 0.07% 325

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advisor Partners's NKTR Position: Q3 2019 in Review

Advisor Partners sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 479 shares — an estimated $255K sold.

Advisor Partners first reported a position in NKTR in Q4 2017 and held it in 7 quarters. The position peaked at $628K in Q1 2018. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • Advisor Partners reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Advisor Partners sold 479 Nektar Therapeutics shares in Q3 2019, an estimated $255K.
  • Advisor Partners first reported a position in Nektar Therapeutics in Q4 2017 and held it in 7 quarters.
  • Advisor Partners's Nektar Therapeutics position peaked at $628K in Q1 2018.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Advisor Partners's 13F filing for Q3 2019, filed 16 Oct 2019.